Pain & Central Nervous System Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pain & Central Nervous System Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Merz Pharmaceuticals
Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201Botulinum neurotoxin type a free from complexing proteins at Annual Movement Disorders Society Meeting
June 22nd, 2009
Results from two randomized, active-controlled clinical trials in patients with blepharospasm and cervical dystonia -- one placebo-controlled spasticity trial and one upper limb spasticity trial -- were presented at the Movement Disorder Society (MDS) 13th annual International Congress in Paris, France. The studies were sponsored by Merz Pharmaceuticals, which plans to file a Biologic License Application (BLA) for NT-201 in the USA in the near future. "The results of these studies reaffirm our beliefs that NT-201 (Xeomin(R); botulinum neurotoxin free from complexing proteins), can be used to potentially aid focal dystonia and post-stroke spasticity sufferers," said Eric...
Source: Pain & Central Nervous System Week (2009-06-22)
|
